

5 years
 Quanto USD

Terms and Conditions

Outperformer Certificate on Novartis AG, Pfizer Inc, Bayer AG and GlaxoSmithKline PLC

(**) A corporate action on Pfizer Inc occurred on 17 November 2020 (Spin Off)

CONTACT INFORMATION:

Mikko Pesonen
 Global Markets | Cross Asset Solutions
 mikko.pesonen@sgcib.com | +46 8 503 368 56

Product Description

ISIN Code	XS2175766281
Common Code	217576628
Issue Size / Aggregate Nominal Amount	USD 540,000 (i.e. 540 Notes)
Specified Denomination	USD 1,000
Specified Currency	USD
Issue Price	100% of the Aggregate Nominal Amount
Capital Protection	No
Guarantor	Société Générale
Issuer	SG Issuer
Minimum Investment	USD 130,000 (i.e. 130 Notes)
Minimum Trading	USD 1,000 (i.e. 1 Note)

Dates

Launch Date	23 October 2020
Schedule(0)	23 October 2020, 23 November 2020, 23 December 2020, 25 January 2021 and 23 February 2021
Issue Date	30 October 2020
Interest Commencement Date	Not Applicable
Valuation Date(1)	23 October 2025 (i.e. "last Valuation Date")
Maturity Date	30 October 2025

Key Parameters

Underlying(s): The following Shares (each an "Underlying(k)" and together the "Basket") as defined below:

k	Company	Bloomberg Ticker	Exchange	Website	Strike
1	Novartis AG	NOVN SE	Six Swiss Exchange	www.novartis.com	CHF 79.824
2	Pfizer Inc	PFE UN	New York Stock Exchange	www.pfizer.com	(**) USD 36.2685385641 = 0.947949 x USD 38.2600103631
3	Bayer AG	BAYN GY	Frankfurt Stock Exchange (Xetra)	www.bayer.com	EUR 48.609
4	GlaxoSmithKline PLC	GSK LN	London Stock Exchange	www.gsk.com	GBp 1,333.4

AverageBasketPerformance(1, Strike(k) (k from 1 to 4))	means the Arithmetic Average, for k from 1 to 4 of Performance(1, k, Strike(k) (k from 1 to 4))
Performance(1, k, Strike(k) (k from 1 to 4))	means (S(1,k) / Strike(k)) - 100%
S(i,k) (i within Schedule(0) or i=1) (k from 1 to 4)	means in respect of any Valuation Date(i), the Closing Price of the Underlying(k)
Strike(k) (k from 1 to 4)	means AverageTimePrice({Schedule(0)},k) for Novartis AG: Strike(1) = CHF 79.824 for Pfizer Inc: Strike(2) = USD 36.2685385641 for Bayer AG: Strike(3) = EUR 48.609 for GlaxoSmithKline PLC: Strike(4) = GBp 1,333.4
AverageTimePrice({Schedule(0)},k) (k from 1 to 4)	means the Arithmetic Average, for i within Schedule(0), of Price(i,k)
Price(i,k)(i within Schedule(0)) (k from 1 to 4)	means S(i,k)

Final Redemption

Final Redemption Amount	<p>Unless previously redeemed, the Issuer shall redeem the Notes on the Maturity Date, in accordance with the following provisions in respect of each Note:</p> <p>Scenario 1:</p> <p>If on Valuation Date(1), AverageBasketPerformance(1,Strike(k),(k from 1 to 4)) is higher than or equal to 0%, then:</p> $\text{Final Redemption Amount} = \text{Specified Denomination} \times [100\% + \text{Min}(110.94212\%; 277.3553\% \times \text{AverageBasketPerformance}(1,\text{Strike}(k),(k \text{ from } 1 \text{ to } 4)))]$ <p>Scenario 2:</p> <p>If on Valuation Date(1), AverageBasketPerformance(1,Strike(k),(k from 1 to 4)) is lower than 0%, then:</p> $\text{Final Redemption Amount} = \text{Specified Denomination} \times [100\% + \text{AverageBasketPerformance}(1,\text{Strike}(k),(k \text{ from } 1 \text{ to } 4))]$
-------------------------	---

General Information

Calculation Agent	Société Générale, Tour Société Générale, 17 cours Valmy, 92987 Paris La Défense Cedex, France
Governing Law	English Law
Type of Structured Notes	Share Linked Notes
Non-Exempt Offer Jurisdiction(s)	<p>None - only private placement</p> <p><i>The Notes are not offered to the public in the European Economic Area. Any resale of the Notes on the secondary market must fulfil at least one of the exemptions set out in Article 3.2 of the Directive 2003/71/EC (as amended, the Prospectus Directive), or should be qualified as a public offer.</i></p>
Listing/Trading	None
Selling Restrictions	For selling restrictions and other details see the Final Terms relating to this issue of this Note together with the Debt Issuance Programme Prospectus and any Supplement(s).
U.S. federal income tax considerations	The Notes are not Specified Notes for purposes of Section 871(m) Regulations.

Payment Business Day Convention	Following Payment Business Day
Financial Centre(s)	New York
Clearing	Clearstream Banking / Euroclear Bank S.A/N.V.
TEFRA Rules	Not Applicable
Form of Notes	Non-US Registered Global Note registered in the name of a nominee for a common depository for Euroclear and Clearstream
Secondary Market	<p>Under normal market conditions, Société Générale or an entity of its group ensures a daily secondary market during the life of the product by providing bid and offer prices expressed as percentages of the specified denomination and the difference between the bid and offer prices (the spread) will not be more than 1% of such specified denomination.</p> <p>In the event of repurchase of the Securities on the secondary market, costs and charges within the meaning of Directive 2014/65 of the European Parliament and of the Council on Markets in Financial Instruments (known as MIF2) will be calculated on the effective date as an exit cost equal to the difference between the fair value of the product as determined by Société Générale or an entity of its group and the price at which Société Générale or an entity of its group actually buys the product. For a request for repurchase on the secondary market, Société Générale or an entity of its group may provide ex-ante, the estimated calculation of the exit cost.</p> <p>If Société Générale is required from a regulatory point of view to provide an annual ex-post report, this report shall indicate the costs actually withheld on the product over the past period.</p>

Commissions and Remunerations

Commissions and Other Remunerations	<p>Société Générale grants its relevant distributor a discount on the Issue Price of up to 1% per annum (calculated on the basis of the term of the Notes) of the nominal amount of the Notes effectively placed by such distributor.</p> <p>If under any applicable laws or regulations (including, if applicable, the Markets in Financial Instruments Directive 2014/65/EU (MiFID II)) a distributor (the "Interested Party") is required to disclose to prospective investors in the Notes further information on any remuneration that Société Générale pays to, or receives from, such Interested Party in respect of the Notes, the Interested Party shall be responsible for compliance with such laws and regulations and investors may request such further information from the Interested Party. In addition, Société Générale may provide further information to its own clients upon request.</p>
-------------------------------------	--

Disclaimers

IMPORTANT WARNING

Investors must read carefully the information provided in the section "Important information for investors" of the terms and conditions. In particular, the attention of the investors is drawn to the following:

Credit risk: Investors take a credit risk on the Issuer, and ultimately on Société Générale as guarantor of the obligations of the Issuer in respect of the product according to the terms and conditions of the guarantee (available at the Guarantor's office upon request). Thus Société Générale's insolvency may result in the partial or total loss of the invested amount. The market value of the product can decrease significantly below its nominal value as a result of Société Générale's creditworthiness.

Recourse limited to the Guarantor: By investing in this product investors acknowledge that they shall have no recourse against the Issuer in the event of a payment default by the Issuer with respect to any amount due under the product, i.e. no investor has the right to institute any proceeding or to otherwise assert a claim against the Issuer of the product to enforce the relevant payment under the product. However, this is without prejudice to the investors' rights under the guarantee of the Guarantor.

Bail-in: The Bank Recovery and Resolution Directive (BRRD) provides "Resolution Authorities" across the European Union with a comprehensive set of tools to deal with failing European financial institutions by using amongst other things the "bail-in". If the Issuer and/or the Guarantor becomes subject to resolution measures in the form of bail-in, investor's claim may be reduced to zero, converted into equity or its maturity may be postponed. This may result in losses on the invested amount, regardless of the capital protection of the product, if any.

Information when products include a risk of capital loss : For products which include a risk of capital loss, the redemption value of such products may be less than the amount initially invested. In a worst case scenario, investors could sustain the loss of their entire investment. Moreover, regardless the level of the capital protection, the investor may lose part or all of the initially invested amount before the maturity date, if the product is sold by the investor.

Events affecting the underlying instrument(s) or hedging transactions: In order to take into account the consequences of certain events affecting the underlying instrument(s) on the product or hedging transactions, the product's documentation provides for (a) mechanisms to adjust or substitute underlying instrument(s), (b) the deduction of the increased cost of hedging from any due amount, (c) monetization and accordingly, de-indexation of the pay-off formula for all or part of the amounts payable under the product from the underlying instrument(s), and (d) the early redemption of the product by the Issuer. Any of these measures may result in losses on the product regardless of the capital protection of the product, if any.

U.S. Selling Restrictions ("Regulation S U.S. Person"):

The Notes described herein are not U.S. Exempt Securities. Accordingly, the Notes have not been registered under the U.S. Securities Act of 1933 and may not be offered, sold, pledged or otherwise transferred at any time except in an "offshore transaction" (as defined under Regulation S) to or for the account or benefit of a Permitted Transferee. A "Permitted Transferee" means any person who: (a) is not a U.S. person as defined in Rule 902(k)(1) of Regulation S; (b) is not a person who comes within any definition of U.S. person for the purposes of the U.S. Commodity Exchange Act (CEA) or any rule of the U.S. Commodity Futures Trading Commission (CFTC Rule), guidance or order proposed or issued under the CEA (for the avoidance of doubt, any person who is not a "Non-United States person" defined under CFTC Rule 4.7(a)(1)(iv), but excluding, for purposes of subsection (D) thereof, the exception for qualified eligible persons who are not "Non-United States persons", shall be considered a U.S. person) and (c) is not a "U.S. Person" for purposes of the final rules implementing the credit risk retention requirements of Section 15G of the U.S. Securities Exchange Act of 1934, as amended (the U.S. Risk Retention Rules) (a Risk Retention U.S. Person). The Notes are available only to, and may only be legally or beneficially owned at any time, by Permitted Transferees.

By its purchase of a Note, each purchaser will be deemed or required, as the case may be, to make certain acknowledgements, representations and agreements set out in the base prospectus.

Section 871(m) of the U.S. Internal Revenue Code of 1986:

U.S. Treasury regulations issued under Section 871(m) of the U.S. Internal Revenue Code of 1986 (**Section 871(m) Regulations**) generally impose a 30% withholding tax on dividend equivalents paid or deemed paid (within the meaning of the relevant Section 871(m) Regulations) to a non-United States holder (a **Non-U.S. Holder**) with respect to certain financial instruments linked to U.S. equities or indices that include U.S. equities (**U.S. Underlying Equities**). Specifically, Section 871(m) Regulations will generally apply to Notes issued on or after 1 January 2017 and that substantially replicate the economic performance of one or more U.S. Underlying Equity(ies) as determined by the Issuer on the date for such Notes as of which the expected delta of the product is determined by the Issuer based on tests in accordance with the applicable Section 871(m) Regulations (for the purposes of the relevant notices, such Notes are deemed “delta-one” instruments) (**Specified Notes**). Notes linked to U.S. Underlying Equities which the Issuer has determined not to be a Specified Note will not be subject to withholding tax under Section 871(m) Regulations. If one or more of the U.S. Underlying Equities are expected to pay dividends during the term of the Specified Note, withholding generally will still be required even if the Specified Note does not provide for payments explicitly linked to dividends. Investors are advised that in withholding this tax, the Issuer will regularly apply the general tax rate of 30% to the payments subject to U.S. provisions (or amounts deemed payments) without regard to any applicable treaty rate. Therefore, in such cases, an investor’s individual tax situation will not be taken into account.

The applicable Final Terms will specify if the Notes are Specified Notes or Zero Estimated Dividends Securities. In the case of Notes that are Specified Notes, but not Zero Estimated Dividends Securities, the applicable Final Terms will specify whether the Issuer or its withholding agent will withhold tax under Section 871(m) Regulations and the rate of the withholding tax. In the case of Notes that are Zero Estimated Dividends Securities, the applicable Final Terms, will specify the rate of the withholding tax to be zero.

Investors are advised that the Issuer’s determination is binding on all Non-U.S. Holders of the Notes, but it is not binding on the United States Internal Revenue Service (**IRS**) and the IRS may therefore disagree with the Issuer’s determination. The rules of Section 871(m) Regulations require complex calculations in respect of the instruments that include U.S. Underlying Equities and application of these rules to a specific issue of Notes may be uncertain. Consequently the IRS may determine they are to be applied even if the Issuer initially assumed the rules would not apply. There is a risk in such case that Noteholders are subject to withholding tax ex post. As neither the Issuer nor the withholding agent will be required to gross up any amounts withheld in connection with a Specified Note, Noteholders will receive smaller payments in such case than they would have received without withholding tax being imposed.

Investors should consult their tax adviser regarding the potential application of Section 871(m) Regulations to their investment in the Notes

IMPORTANT INFORMATION FOR INVESTORS

Prior to investing in the product, investors should seek independent financial, tax, accounting and legal advice.

General selling restrictions: It is each investor’s responsibility to ascertain that it is authorized to subscribe for, or invest into, or to on-sell this product. Further, the underlying instrument(s) of certain products may not be authorised to be marketed in the country(ies) where such products are offered. The attention of investors is drawn to the fact that the offering of these products in this (these) country(ies) in no way constitutes an offer, or an invitation to make an offer, to subscribe to, or purchase, the underlying instrument(s) in such country(ies).

Information on commissions, remunerations paid to, or received from third parties: If, under applicable laws and regulations, any person (the “Interested Party”) is required to disclose to prospective investors in the product any commission or remuneration that Société Générale and/or the Issuer pay(s) to, or receives from, such Interested Party in respect of the product, the Interested Party shall be solely responsible for compliance with such laws and regulations.

Market risk: The product may at any time be subject to significant price movement which may in certain cases lead to the loss of the entire amount invested. Certain products may include embedded leverage, which amplifies the variation, upwards or downwards, in the value of the underlying instrument(s) which may result, in a worst case scenario, in the partial or total loss of the invested amount.

Risk relating to unfavourable market conditions: The fluctuations in the marked-to-market value of certain products may require the investor to make provisions or resell the products in whole or in part before maturity, in order to enable the investor to comply with its contractual or regulatory obligations. As a consequence, the investor may have to liquidate these products under unfavourable market conditions, which may result in the partial or total loss of the invested amount. This risk will be even higher if these products include leverage.

Liquidity risk: This product entails a materially relevant liquidity risk. Certain exceptional market circumstances may have a negative effect on the liquidity of the product. The investor may not be able to sell the product easily or may have to sell it at a price that significantly impacts how much he gets back. This may entail a partial or total loss of the invested amount.

Information in the event of a buy back by Société Générale or of an early termination of the product: Société Générale may commit to ensure a secondary market. The performance of this commitment shall depend on (i) general market conditions and (ii) the liquidity conditions of the underlying instrument(s) and, as the case may be, of any other hedging transactions. The price of such products (in particular, the “bid/offer” spread that Société Générale may propose for the repurchase or early termination of such products) will include, inter alia, the hedging and/or unwinding costs generated by such a buy back for Société Générale. Société Générale and/or its subsidiaries cannot assume any responsibility for such consequences and for their impact on the transactions relating to, or investment into, the relevant products.

Information on data and/or figures drawn from external sources: The accuracy, completeness or relevance of the information which has been drawn from external sources is not guaranteed although it is drawn from sources reasonably believed to be reliable. Subject to any applicable law, neither Société Générale nor the Issuer shall assume any liability in this respect.

Information on simulated past performance and/or on future performance and/or on past performance: The value of your investment may fluctuate. When simulated past performance or past performance is displayed, the figures relating thereto refer or relate to past periods and are not a reliable indicator of future results. This also applies to historical market data. When future performance is displayed, the figures relating to future performance are a forecast and are not a reliable indicator of future results. Furthermore, where past performance or simulated past performance relies on figures denominated in a currency other than that of the country of residence of an investor, the return for such investor may increase or decrease as a result of currency fluctuations. Finally, when past or future performance or simulated past performance is displayed, the potential return may also be reduced by the effect of commissions, fees, taxes or other charges borne by the investor.

Currency exchange risk: When the underlying asset(s) is/are quoted and/or expressed in a foreign currency and/or, in the case of an index or an asset basket, it contains components expressed and/or quoted in one or several foreign currency(ies), the value of the investment may increase or decrease as a result of the value of such currency(ies) against the euro or any other currency in which the product is expressed, unless the product includes a currency exchange guarantee.

Conflict of Interest: The valuation of a product may be linked to the spot price or the fixing of underlying financial instruments or other asset types (the “underlying assets”). At any time, Société Générale and its affiliates may trade in such underlying assets on own account or on behalf of their clients who may have similar or opposite interests to investor’s own, or act, without limitation, as derivatives counterparty, hedging party, issuer, market maker, broker, structurer, advisor, distributor, placing agent, guarantor, asset manager, custodian or calculation agent in relation to such underlying assets, which might have an impact on such underlying assets’ performance, liquidity or market value. Therefore, potential conflicts of interest may arise between the different divisions of Société Générale Group acting on such underlying assets on own account or on behalf of their clients, and investor’s own. However, conflicts of interest are identified, prevented and managed in accordance with Société Générale’s conflict of interest policy which summary has been communicated to the investor or is available upon request to his usual Société Générale contact.

Benchmarks: Investors in floating rate Notes and/or indexed on certain underlyings which are considered as benchmarks are exposed to the risk that : 1) such benchmarks may be subject to methodological or other changes which could affect their value, or 2) (i) may become not compliant with applicable laws and regulations (such as the Regulation (EU) No. 2016/1011 of the European Parliament and of the Council of 8 June 2016 (the **Benchmarks Regulation**)) ; (ii) may cease to be published (possible cessation of LIBOR publication or planned cessation of EONIA both after December 2021), or (iii) the supervisor or administrator of any such benchmark may make a statement that the relevant benchmark is no longer representative, and as a consequence the relevant benchmark may be replaced by another benchmark.

Authorisation: Société Générale is a French credit institution (bank) that is authorised and supervised by the European Central Bank (ECB) and the Autorité de Contrôle Prudentiel et de Résolution (ACPR) (the French Prudential Control and Resolution Authority) and regulated by the Autorité des marchés financiers (the French financial markets regulator) (AMF).

For any country of the European Economic Area or for the United Kingdom (i) in which the product is not admitted to trading on a regulated market and (ii) not expressly referred to, in this document, as a country in which a non-exempt offer of the product is authorised, this PRODUCT IS OFFERED ON AN EXEMPT OFFER BASIS and no prospectus has been approved in that country by the local regulator. The product cannot thus be distributed in that country by way of an offer, or an invitation to make an offer of securities to the public, as defined in Regulation (EU) 2017/1129 (the **Prospectus Regulation**).

Confidentiality: This document is confidential and may be neither communicated to any third party (with the exception of external advisors on the condition that they themselves respect this confidentiality undertaking) nor copied in whole or in part, without the prior written consent of Société Générale.